• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

Shift Bioscience

mitochondria

  • Please log in to reply
No replies to this topic
⌛⇒ MITOMOUSE has been fully funded!

#1 caliban

  • Admin, Advisor, Director
  • 8,953 posts
  • 1,807
  • Location:UK

Posted 29 March 2019 - 08:18 PM


https://shiftbioscience.com/
 

We have identified small molecule ‘Shift’ drugs that combat diverse age-accumulated mitochondrial genome damage

 
 

We will minimize costs and timescales for clinical development of Shift drugs by first targeting the orphan disease MELAS, which is caused by inherited mitochondrial dysfunction. A clinical trial for MELAS requires fewer participants due to the rarity of the disease and the larger degree of unmet clinical need. Drug efficacy is easier to demonstrate due to clearer biological/clinical endpoints.







0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users